Strengthening multi-center randomized controlled trial to improve clinical research of ocular fundus diseases in China
10.3760/cma.j.issn.1005-1015.2015.03.002
- VernacularTitle:开启我国眼底病临床研究的新思路——基于中心性浆液性脉络膜视网膜病变多中心临床研究历程的思考
- Author:
Mingwei ZHAO
- Publication Type:Journal Article
- Keywords:
Central serous chorioretinopathy/therapy;
Multicenter study;
Randomized controlled trials as topic;
Editorial
- From:
Chinese Journal of Ocular Fundus Diseases
2015;31(3):218-220
- CountryChina
- Language:Chinese
-
Abstract:
Multicenter randomized controlled studies can recruit more subjects in a relatively short period of time,avoiding the bias of single research institution studies,resulting in reliable conclusions and providing strong guidance to clinical practice.They are the most scientific and most reliable methods to evaluate clinical researches.However,there are few multicenter clinical trials in China as Chinese doctors are often trapped in difficulties in clinical research,including imperfect research system,lack of experience,capital investment deficient,the tension in the doctor-patient relationship and so on.Although the above problems are related to medical system architecture of our country in a certain extent,compared with the overseas,we also have our own advantages,such as resource of our patients,doctors,and diseases type.Pay attention to discovering of new type of diseases,looking for genetics discipline,and exploring new medical technology is an important task of clinical research.We have plenty of high level ophthalmology centers at present,which provide favorable conditions for launching multi-center clinical trial studies.We have good reasons to believe that,if we can effectively exploit the resources in our hands,carefully observe and discover clinical problems,there will be more convincing clinical results present in the world after bring up hypothesis boldly while prove it conscientiously and carefully.
